bioRxiv · 10.1101/2022.12.30.522303
Specificity, synergy, and mechanisms of splice-modifying drugs
Abstract
Drugs that target pre-mRNA splicing hold great therapeutic potential, but the quantitative understanding of how these drugs work is limited. Here we introduce mechanistically interpretable quantitative models for the sequence-specific and concentration-dependent behavior of splice-modifying drugs. Using massively parallel splicing assays, RNA-seq experiments, and precision dose-response curves, we obtain quantitative models for two small-molecule drugs, risdiplam and branaplam, developed for treating spinal muscular atrophy. The results quantitatively characterize the specificities of risdiplam and branaplam for 5 splice site sequences, suggest that branaplam recognizes 5 splice sites via two distinct interaction modes, and disprove the prevailing two-site hypothesis for risdiplam activity at SMN2 exon 7. The results also show that anomalous single-drug cooperativity, as well as multi-drug synergy, are widespread among small-molecule drugs and antisense-oligonucleotide drugs that promote exon inclusion. Our quantitative models thus clarify the mechanisms of existing treatments and provide a basis for the rational development of new therapies.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ishigami, Y., Wong, M. S., Marti-Gomez, C., Ayaz, A., Kooshkbaghi, M., Hanson, S., McCandlish, D. M., Krainer, A. R., Kinney, J. B.. 2022-12-31. Specificity, synergy, and mechanisms of splice-modifying drugs. https://doi.org/10.1101/2022.12.30.522303
Cite the original work for its findings. Save a collection to share your selection of sources.